Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-3]
• Quality of Life and Physical Health-Related Quality of Life: Parathyroid Hormone (PTH) therapy likely improves physical health-related quality of life compared to conventional therapy, with a mean difference (MD) of 3.4 (95% confidence interval (CI): 1.5–5.3), slightly exceeding the minimally important difference (3.0), based on moderate-certainty evidence. Standard treatment with calcium and/or vitamin D alone was associated with statistically significantly lower quality of life scores in patients with hypoparathyroidism compared to controls.
• Reduction in Active Vitamin D and Calcium Dose: PTH therapy significantly increased the likelihood of a 50% or greater reduction in active vitamin D and calcium doses, with a relative risk (RR) of 6.5 (95% CI: 2.5–16.4), translating to 385 more patients per 1000 achieving this reduction (high-certainty evidence).
• Calcium Homeostasis: No statistically significant differences in serum calcium levels were observed between PTH and control groups (MD: -0.01; 95% CI: -0.09, 0.06; P = 0.71). A trend toward lower 24-hour urinary calcium in the PTH group was noted but did not reach statistical significance (MD: -1.43; 95% CI: -2.89, 0.03; P = 0.06).
• PTH therapy may increase the risk of hypercalcemia compared to conventional therapy (RR = 2.4, 95% CI 1.2-5.04, low certainty).
• The incidence of serious adverse events was similar between the PTH and control groups (RR 1.35; 95% CI 0.58, 3.16; P = 0.49).
• There is no population types or subgroups information available in the reviewed studies.